The KiTZ is particularly committed to patients who were not cured by established treatment methods. At the KiTZ we conduct innovative clinical trials in close cooperation with other pediatric oncology centers in Germany, Europe, and the US. In these so-called phase I/II clinical trials, patients are treated with new medications that are still in the early stages of development and treatment is tightly controlled. To do this, we first create an individual molecular profile of the tumor using state-of-the-art diagnostic methods and check to what extent it is suitable for inclusion in a particular study. If inclusion in a study is not possible, we will use the molecular data to determine if it is possible to perform case-by-case treatment.
In the KiTZ program "Translational Pediatric Oncology" we are developing such innovative clinical studies. The goal is to develop new diagnostic procedures, medicines and therapy concepts for childhood tumors based on the findings of basic research.
An example is our INFORM study whose aim is to help develop new treatments for children and adolescents who have relapsed after cancer. For this purpose, the tumors of patients who have relapsed and for whom there are no more established treatment concepts are genetically characterized as accurately as possible.
Patients who are ensured in Germany: Please use the "Merkblatt" in the download section for your application. Please make sure you fill out the form completely and according to our guidelines. Always send your application via post (and not via e-mail).
Consultation of the KiTZ Trial Unit (ZIPO)
Prof. Dr. Olaf Witt, PD. Dr. Till Milde, Dr. Cornelis van Tilburg
Tel.: +49 6221 - 56 37082 (registration: Linda Keilbach)
Consultation „Hereditary cancer predisposition“
Prof. Dr. Stefan Pfister
Tel.: +49 6221 - 42 4618
- Molecular diagnostic studies at the KiTZ
- Informationen der pediatric oncological and hematological outpatient clinic of Heidelberg University hospital